Understand the source comparison
Best Peptides for Patellar Tendinitis: Research Comparison
BPC-157 Upregulates VEGF, modulates FAK-paxillin pathway, accelerates fibroblast migration to injury sites 250–500mcg/day Daily subcutaneous near injury site Animal models show 40% greater tensile strength at 4 weeks when combined with mechanical loading (J Or
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- Upregulates VEGF, modulates FAK-paxillin pathway, accelerates fibroblast migration to injury sites
- 250–500mcg/day
- Daily subcutaneous near injury site
- Animal models show 40% greater tensile strength at 4 weeks when combined with mechanical loading (J Orthop Res 2019)
- Strongest evidence for localized tendon repair. Proximity to injury site matters
- TB-500 (Thymosin Beta-4)
- Binds actin, promotes angiogenesis and collagen deposition, increases tendon cellularity
- 2–5mg/week acute phase, 2mg biweekly maintenance
- Weekly or biweekly subcutaneous
- Equine flexor tendon studies show dose-dependent tissue remodeling (Am J Pathol)
- Longer half-life allows flexible dosing. Works systemically rather than locally
- Ipamorelin / CJC-1295
- Stimulates endogenous GH and IGF-1 secretion, supports systemic collagen turnover
- 200–300mcg/day (Ipamorelin)
- Daily subcutaneous
- Correlation data in older populations with suppressed baseline GH (Sports Med 2020 review)
- Indirect mechanism. Best as adjunct rather than primary tendon intervention
- GHK-Cu (Copper Peptide)
- Promotes collagen and glycosaminoglycan synthesis, modulates metalloproteinases
- 1–3mg/day
- Daily subcutaneous or topical
- Wound healing models show improved collagen density. Limited tendon-specific data
- Promising for skin and fascial tissue. Tendon evidence weaker than BPC-157 or TB-500